Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline characteristics of pan-regional observational data from more than 17,000 patients

International Journal of Clinical Practice

Volumn 63, Issue 11, 2009, Pages 1578-1588

  Karagianis, J ^a   Novick, D ^a   Pecenak, J ^b   Haro, J M ^c   Dossenbach, M ^a   Treuer, T ^d   Montgomery, W ^e   Walton, R ^f   Lowry, A J ^f  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d Lilly Hungaria Kft   (Hungary)

^e Eli Lilly Australia   (Australia)

^f Intercontinental Information Sciences   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; ASIA; CLINICAL GLOBAL IMPRESSION SCALE; EMPLOYMENT; EUROPE; FEMALE; HEALTH STATUS; HOUSING; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; NORTH AFRICA; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; SOCIAL INTERACTION; SOUTH AMERICA; SOUTHERN EUROPE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; AMBULATORY CARE; CLINICAL TRIAL; ECONOMICS; HEALTH; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RURAL HEALTH; SCHIZOPHRENIA; TREATMENT OUTCOME; URBAN HEALTH;

EID: 70349967831     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02191.x     Document Type: Article

References (38)

1. World Health Organisation. The Global Burden of Disease: 2004 update. Available at: http://www.who.int/healthinfo/global-burden-disease/2004-report- update/en/index.html (accessed February 2009).
2. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PloS Med 2005 2 : e141.
3. Warner R, de Girolamo G. Schizophrenia. Geneva, Switzerland : World Health Organization, 1995.
4. Saha S, Welham J, Chant D, McGrath J. Incidence of schizophrenia does not vary with economic status of the country: evidence from a systematic review. Soc Psychiatry Psychiatr Epidemiol 2006 41 : 338 340.
5. Sartorius N, Shapiro R, Kimura M, Barrett K. WHO international pilot study of schizophrenia. Psychol Med 1972 2 : 422 425.
6. Jablensky A, Sartorius N, Ernberg G et al. Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organisation ten-country study. Psychol Med Mongr Suppl 1992 20 : 1 97.
7. Harrison G, Hopper K, Craig T et al. Recovery from psychotic illness: a 15- and 25- year international follow-up study. Br J Psychiatry 2001 178 : 506 517.
8. Edgerton RB, Cohen A. Culture and schizophrenia: the DOSMD challenge. Br J Psychiatry 1994 164 : 222 231.
9. Sartorius N, Gulbinat W, Harrison G et al. Long-term follow-up of schizophrenia in 16 countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. Soc Psychiatry Psychiatr Epidemiol 1996 31 : 249 258. (Pubitemid 26340963)
10. Hopper K, Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. Schizophr Bull 2000 26 : 835 846.
11. Cohen A, Patel V, Thara R, Gureje O. Questioning an axiom: better prognosis for schizophrenia in the developing world? Schizophr Bull 2008 34 : 229 244.
12. Jablensky A, Sartorius N, Cooper JE et al. Culture and schizophrenia. Criticisms of WHO studies are answered. Br J Psychiatry 1994 165 : 434 436.
13. Haro JM, Edgell ET, Jones PB et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003 107 : 222 232.
14. Haro JM, Edgell ET, Novick D et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005 111 : 220 231. (Pubitemid 40342191)
15. Dossenbach M, Erol A, el Mahfoud Kessaci M et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry 2004 65 : 312 321.
16. Haro JM, Novick D, Suarez D et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006 26 : 571 578. (Pubitemid 44772733)
17. Novick D, Haro JM, Suarez D et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009 108 : 223 230.
18. Dossenbach M, Pecenak J, Szulc A et al. Long-term antipsychotic monotherapy for schizophrenia: Disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiatry 2008 69 : 1901 1915.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC : American Psychiatric Association, 2000.
20. World Health Organization. International Classification of Diseases. Mental and Behavioural Disorders, 10th edn. Geneva, Switzerland : World Health Organization, 1994.
21. Haro JM, Kamath SA, Ochoa S et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003 416 : 16 23.
22. Kind P. The EuroQol instrument: an index of health-related quality of life. In : Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia : Lippincott-Raven, 1996 : 191 201.
23. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 33 : 337 343.
24. International Monetary Fund. World Economic and Financial Surveys World Economic Outlook Database: WEO Groups and Aggregates Information. http://www.imf.org/external/pubs/ft/weo/2008/01/weodata/groups.htm#af (accessed November 2008).
25. The World Bank. Data and Statistics: Country Classification. Available at: (http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,contentMDK: 20420458∼menuPK:64133156∼pagePK:64133150∼piPK:64133175∼ theSitePK:239419,00.html (accessed January 2009).
26. Alem A, Kebede D. Conducting psychiatric research in the developing world: challenges and rewards. Br J Psychiatry 2003 182 : 185 187.
27. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998 317 : 1181 1184.
28. Saxena S, Paraje G, Sharan P et al. The 10/90 divide in mental health research: trends over a 10-year period. Br J Psychiatry 2006 188 : 81 2.
29. Patel V, Kim YR. Contribution of low- and middle-income countries to research published in leading general psychiatry journals, 2002-2004. Br J Psychiatry 2007 190 : 77 8.
30. Zarin DA, Young JL, West JC. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc Psychiatry Psychiatr Epidemiol 2005 40 : 27 35.
31. Chung W, Cho WH, Yoon CW. The influence of institutional characteristics on length of stay for psychiatric patients: a national database study in South Korea. Soc Sci Med 2009 68 : 1137 1144.
32. Dossenbach M, Dyachkova Y, Pirildar S et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry 2006 21 : 251 258.
33. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008 23 : 201 209.
34. Kind P, Hardman G, Macran S UK Population Norms for EQ-5D. Discussion paper 172. Centre for Health Economics, York: Univeristy of York, 1999 1 98.
35. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007 64 : 1123 1131.
36. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005 62 : 247 253.
37. Drake RE, Gates C, Whitaker A, Cotton PG. Suicide among schizophrenics: a review. Compr Psychiatry 1985 26 : 90 100.
38. Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009 360 : 225 235.